
1st International Electronic Conference on Biomedicine
1–26 Jun 2021
Therapeutic Targets, Therapeutic Strategies, Naturally Driven Biomedicines, Pharmaceuticals, Biopharmaceutical Products
- Go to the Sessions
-
- S1. Nanomedicine and Precision Medicine
- S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- S3. Cancer Therapeutics
- S4. Metal-based Therapeutics in Preclinical and Clinical Developments
- S5. Oncolytic Virus-Mediated Immunotherapy
- S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- S10. G-protein-coupled Receptor Family
- S11. Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
- Event Details
All participants of ECB2021 are welcome to submit the extended work to the Biomedicines Special Issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)".
We are pleased to announce the winners of the Best Paper Award and Best Poster Award:
Best Paper Award:
“Drug Targets, and Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment Cancer Stem Cells and Somatic Stem Cells as Potential New”
by Evgenii Skurikhin et al.
Best Poster Award:
“Antibacterial assessment of sodium alginate/gelatin films loaded with propolis extract”
by Natália C. Homem et al.
Welcome from the Chairs
Dear Colleagues,
It is my pleasure to invite you to join the 1st International Electronic Conference on Biomedicine (ECB 2021) that is hosted online by: https://ecb2021.sciforum.net.
ECB 2021 will present the latest research related to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products.
Topics of interest include but are not limited to:
- Nanomedicine and Precision Medicine
- Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- Cancer Therapeutics
- Metal-based Therapeutics in Preclinical and Clinical Developments
- Oncolytic Virus-mediated Immunotherapy
- Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- G-protein-coupled Receptor Family
- Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
ECB 2021 seeks to fulfill this need by offering a completely digital (online) method for running a scientific conference. ECB 2021 will allow its participants to share their latest research results and receive near-instantaneous feedback from biomedical researchers throughout the world through online question and answer sessions and discussion groups. In this way, ECB 2021 will serve as a platform for advancing the state-of-the-art in biomedicines. There is no cost to participate in ECB 2021.
All submitted abstracts will be evaluated by the conference committee. Upon acceptance of their abstract, authors will contribute an extended abstract for the conference proceedings and a slide presentation of their work. Selected papers (need 50% extension compared with the proceedings papers) will be considered for publication in the special issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)", with a 20% discount on the APC after peer-review.
I hope you will choose to be a part of this exciting conference and present your most transformative research on biomedicine.
Conference Secretariat
Ms. Nicole Peng
MDPI Branch Office, Wuhan
E-mail: [email protected]
Ms. Penny Zhang
MDPI Branch Office, Wuhan
E-mail: [email protected]
Ms. Stefanie Li
MDPI Branch Office, Wuhan
E-mail: [email protected]
Conference Chairs

Professor Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA

Dr. Veronique Baud
Faculté de Pharmacie, Paris, France
Conference Committee

Professor Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA

Dr. Muhammad Hanif
The University of Auckland, Auckland, New Zealand

Dr. Zong Sheng Guo
The University of Pittsburgh Cancer Institute, and University of Pittsburgh School of Medicine, Pittsburgh, USA

Dr. Jacek M. Kwiecien
McMaster University, Ontario, Canada

Dr. Masaru Tanaka
University of Szeged, Szeged, Hungary

Professor Alexander Seifalian
The London BioScience Innovation Centre, London, United Kingdom

Dr. Allan Stensballe
Alborg University, Aalborg, Denmark

Professor Ujendra Kumar
The University of British Columbia, Vancouver, Canada

Professor Ciro Isidoro
Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
Session Chairs

Professor Shaker A. Mousa
Albany College of Pharmacy and Health Sciences, Rensselaer, USA
Nanomedicine and Precision Medicine; Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals

Dr. Veronique Baud
Faculté de Pharmacie, Paris, France
Cancer Therapeutics

Dr. Muhammad Hanif
The University of Auckland, Auckland, New Zealand
Metal-based Therapeutics in Preclinical and Clinical Developments

Dr. Zong Sheng Guo
The University of Pittsburgh Cancer Institute, and University of Pittsburgh School of Medicine, Pittsburgh, USA
Oncolytic Virus-Mediated Immunotherapy

Dr. Jacek M. Kwiecien
McMaster University, Ontario, Canada
Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure

Dr. Masaru Tanaka
University of Szeged, Szeged, Hungary
Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry

Professor Alexander Seifalian
The London BioScience Innovation Centre, London, United Kingdom
Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants

Dr. Allan Stensballe
Alborg University, Aalborg, Denmark
Translational Biomarkers in Clinical Biomedicine and Precision Medicine

Professor Ujendra Kumar
The University of British Columbia, Vancouver, Canada
G-protein-coupled Receptor Family

Professor Ciro Isidoro
Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy
Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
Invited Speakers

Prof. Dr. David Bartlett
1. Department of Surgery, Drexel University College of Medicine, Pittsburgh, PA 15212, USA
2. AHN Cancer Institute
Sessions
S1. Nanomedicine and Precision MedicineS2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
S3. Cancer Therapeutics
S4. Metal-based Therapeutics in Preclinical and Clinical Developments
S5. Oncolytic Virus-Mediated Immunotherapy
S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
S10. G-protein-coupled Receptor Family
S11. Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
Video from Invited Speaker
Oncolytic Virus-Mediated Immunotherapy
by Prof.Dr. David Bartlett
List of accepted submissions (50)
Id | Title | Authors | Presentation Video | Presentation Pdf | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-045273 | Neuroprotective Therapies in Spinal Cord Injury, the First and Necessary Step towards the Cure. | N/A | N/A |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
A trauma to the spinal cord involves the massive injury to the white matter and initiates a severe, destructive and extraordinarily protracted inflammation characterized by heavy infiltration by CD68+/CD163-, inflammatory macrophages. Post-traumatic destruction of the spinal cord by phagocytic macrophages along with a marked elevation of pro-inflammatory cytokines, including IFN-γ, IL-1α, IL-1β, IL-6 and of chemokines indicates the need for anti-inflammatory therapies to inhibit and eliminate these damaging processes and to result in neuroprotection. In a rat model of the balloon crush over the mid-thoracic spinal cord from the 3Fogarty catheter placed epidurally a deep area of necrosis and hemorrhage resulting from the trauma is converted into a cavity of injury (COI) filled by necrotic debris and hemorrhage and filling up with excess edema fluid. The COI is defined by progressively severe astrogliosis forming a wall whose thickness grows with a progressive lowering of the numbers of phagocytic macrophages beyond 16 weeks post-SCI. An area of necrosis that is superficial with disruption of a wide area of the surface of the spinal cord, it becomes invaded by granulomatous inflammation from the sub-arachnoid space including macrophages, fibroblasts and blood vessels. The expansion of this type of inflammation, called arachnoiditis, is counteracted by a progressively severe astrogliosis and in time it is often separated from the spinal cord by liquid-containing cystic spaces not unlike the COI. A macrophage count in the COI test has been developed to measure the severity of inflammation and also, to measure the anti-inflammatory effect of a candidate treatment. It involves counting phagocytic macrophages in a standardized fashion at the margin of the COI in consecutive sections of the spinal cord stained with luxol fast blue and haematoxylin and eosin (LFB+H&E). This new analytic method allowed for detection of a powerful anti-inflammatory effect of dexamethasone and two Myxomavirus-derived proteins, Serp-1, with anti-thrombotic/anti-thrombolytic action, and M-T7, a chemokine inhibitor. Each of these 3 agents were administered by a continuous subdural infusion in the vicinity of the SCI for one week and resulted in lowering of the numbers of macrophages by 50-80% with remarkable slowing down of the phagocytosis of myelin-rich necrotic debris and hemorrhages in the COI, indicating the need for much longer administration to eliminate the debris by drug-reduced phagocytosis. While administration of dexamethasone has proven to result in severe toxicity leading to shock, both viral proteins were well tolerated. Continuous subdural administration of Serp-1 for 8 weeks resulted in elimination of phagocytic macrophages from the COI. This is the first pre-clinical study demonstrating that an anti-inflammatory treatment can effectively shorten the inflammatory disease and result in neuroprotection. The inhibition and elimination of severe, destructive inflammation post-SCI is the first and necessary step in a multistep therapy leading to the cure of severe spinal cord trauma. Once inflammation is eliminated, implantation of a bridge into the COI that will support axonal regeneration in neuroregenerative therapies can be contemplated. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-043888 | Assessment of essential oil-loaded nanofibrous mats against the Escherichia virus MS2, a mimetic of SARS-CoV-2, for potential applications as inner layers in individual protection masks | , , , |
![]() |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
In December 2019, a novel strain of coronavirus, SARS-CoV-2, was identified. Infected patients revealed symptoms of fever, cough (dry), sore throat, and fatigue, which began manifesting after 5 days of incubation. Hoping to prevent transmission, many countries adopted a mandatory mask use in closed public spaces. However, most mask options display a passive action against COVID-19. To overcome such restrictions, this work proposes the incorporation of anti-viral essential oils (EOs) loaded onto a nanofibrous layer that can be adapted to both community and commercial masks. Twenty EOs selected based on their antimicrobial nature were examined for the first time against the Escherichia virus MS2. The most effective were the lemongrass (LO), Niaouli (NO) and eucalyptus (ELO) with a minimum inhibitory concentration (MIC) of 356.0 mg/mL, 365.2 mg/mL and 586.0 mg/mL, respectively. Polycaprolactone (PCL) and cellulose acetate (CA) were prepared individually at 14 wt% in chloroform/dimethylformamide (DMF) and 10 wt% in acetone/DMF, respectively, and combined at 3:1 ratio. Polymeric solutions were then processed via eletrospinning with processing parameters being optimized to 24.7 kV, 3.2 mL/h and 21 cm. Uniform, beadless nanofibers were obtained. Mats were characterized as mechanically resilient, to endure movements arising from mask positioning, and hydrophobic in nature, to repel droplets coming from the exterior. Loading of the nanofibrous mats was accomplished via physisorption using the free -OH groups of the CA as linkers. Mats were loaded with the EOs at MIC concentration for 72 h (saturation). Presence of the EOs was confirmed along the mats. Antimicrobial testing via halo determination, verified their diffusion abilities. More importantly, time-kill kinetics testing of the loaded mats attested to the EOs capability to fight the virus MS2 even when bonded to the nanofibers. Data demonstrated the potential of these EOs-loaded PCL/CA nanofibers mats to work as COVID-19 active barriers for individual protection masks. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-041757 | Protein nanocages for anticancer metal-based drug delivery | , |
![]() |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Supramolecular protein assembly, such as cages, rings, and tubes can be used as reaction vessels and molecular templates for applications in catalysis, imaging and drug delivery.1 Ferritin (Ft) is a member of ferroxidase family of enzymes that forms a spherical nanocage. It sequesters iron by concentrating it in its internal cavity for storage and detoxification.2 Ft is very promising as a drug loading and releasing system since it is non-immunogenic, bio-compatible, highly stable, soluble in the bloodstream. It can be internalized via Ft-binding receptors (like transferrin receptor 13 or Scara54) that are over-expressed in a variety of malignant cells. Well established metallodrugs like cisplatin,5 carboplatin,6 a Pt-terpyridine compound,7 three different gold-based anticancer compounds (Auoxo3, Au2phen, Auoxo4),8-9 a bimetallic Pt-Au compound10, a bimetallic Pt-As compound and a di-ruthenium complex11 have been trapped within the Ft nanocages, taking advantage of the alkaline pH disassembly/reassembly protocol. The drug-loaded nanocomposites have been characterized by circular dichroism, to evaluate the protein secondary structure content upon drug encapsulation, and by UV-vis absorption spectroscopy, to assess the drug loading within the protein cage. ICP-MS allowed to quantify the amount of drug trapped inside the nanocage and to define metal/Ft stoichiometry, while X-ray crystallography unveiled the metallodrugs binding sites on the proteins structure and the nature of the interaction of the different compounds with Ft. The compounds often degrade upon encapsulation within the protein cage; metal-containing fragments coordinate Cys or His side chains. However, the coordination does not affect the overall cytotoxicity of the encapsulated anticancer agents, since many molecules of the metallodrugs remain trapped in the bulk within the inner core of the cage. Biological activity studies show that, even though the presence of the cage reduces the overall toxicity of the metallodrugs, the adducts of the selected compounds with Ft are generally more selective towards cancer cells than to non-malignant cells. Altogether these data indicate that encapsulation of metal-based drugs within Ft nanocages is a promising strategy to deliver these molecules to their final targets.12
|
|||||||||||||||||||||||||||||||||||||||||
sciforum-045094 | The study of natural compounds as antidepressants by bioinformatics methods | , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
According to the World Health Organization, the neuropsychiatric disorders pose an increasingly greater burden on health, society and economy of countries. Currently there are strategies to prevent some of these disorders and there are treatments or means to alleviate their symptoms. In the case of depression, the medication consists of antidepressant drugs. Such drugs can also be used in other conditions like anxiety, pain or insomnia. A shortcoming of the currently used antidepressants is the occurrence of side effects that sometimes are unbearable for the patient. In this respect, a promising direction is the usage of medicinal plants. Plant parts are rich in phytochemicals that could be beneficial in mental disorders by acting on various targets. Here we investigated the antidepressant effect of ten natural compounds from sage, mint and citrus. The biological activity of these compounds was investigated by calculating ki values and affinities for dopamine receptor D2, serotonin transporter (SERT) and 5-hydroxytryptamine receptor 1A (5HT1A) using Almond-Pentacle software. Our results showed that resveratrol and rutin could be efficient antidepressants. Acknowledgments. The study was supported by UEFISCDI through the projects PN-III-P2-2.1-PED2019-1471 “New biocompatible shagaol and curcuminoid-like products used as adjuvantes in cancer radiotherapy” and PN-III-P1-1.2-PCCDI-2017-0728 “Integrated project for the development of technologies dedicated to advanced medical treatments”. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-044540 | GPCRs of diverse physiologic and pathologic effects with their fingerprints in COVID-19 | , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
G-protein-coupled receptors (GPCR), a seven-transmembrane α-helical domain protein, contribute to many physiologic functions including vision, olfaction and taste and also to several pathologic processes including hypersensitivity to angiotensin II, inflammatory and vascular diseases [1, 2]. GPCRs in binding with agonistic ligands adopt a proton-transport dependent conformational change and activate cytoplasmic heterotrimeric G proteins (Gα/Gβγ subunits) through dissociation of Gα from Gβγ complex and exchange of GTP for GDP in Gα subunit [3, 4]. This activates a second messenger including cAMP, Ca2+, diacylglycerol which induces some intracellular pathways such as MAPK, PI3K-Akt and Ras and Rho GTPases [5]. Moreover, GPCR activation promotes receptor phosphorylation by GPCR-kinase with subsequent binding of β-arrestin which induces G-protein independent signaling cascades [6, 7]. COVID-19-induced inflammatory cascade has been attributed to ACE2 downregulation and imbalance of proinflammatory ACE/AngII/AT1R and anti-inflammatory ACE2/Angiotensin(1-7)/Mas axes in favor of the former [8]. AT1R, AT2R and Mas receptors belong to GPCR family [9, 10]. While sustained AngII activation of AT1R induces inflammatory responses through G-proteins, angiotensin(1-7) promotes anti-inflammatory effects both via Mas/GPCR receptors and AT1R/GPCR mediated β-arrestin pathway [11]. SARS-CoV2 has been suggested to induce lung edema via activation of GPCRs or modulating G-proteins involved in adenosine-CFTR regulation system and epithelial Na channel function [12]. Complement 5a receptor1 (C5aR1), a member of GPCR family, has recently been proposed to be involved in COVID-19 pathogenesis [13]. GPCR4, which regulates vascular permeability and leukocyte recruitment, has been hypothesized to play a part in SARS-CoV2 infection [14]. References: |
Instructions for Authors
Submissions should be submitted by the authors online by registering at https://ecb2021.sciforum.net/, and using the “Submit Abstract” function once logged into system.
- Scholars interested in participating with the conference can submit their abstract (about 200–250 words covering the areas of manuscripts for the proceedings issue) online at this website up to 16 March 2021.
- The Conference Committee will conduct a pre-evaluation, based on the submitted abstract, of whether the contribution from the authors of the abstract will be welcome for the 1st International Electronic Conference on Biomedicine. All authors will be notified by 31 March 2021 about the acceptance of their abstract.
- If the abstract is accepted for this conference, the author is asked to submit the manuscript optionally along with a PowerPoint and/or video presentation of his/her paper (only PDF), up to the submission deadline of 30 April 2021.
- The conference proceedings papers and presentations will be available at https://ecb2021.sciforum.net for discussion during the time of the conference, 1–26 June 2021, and will be published in Journal Proceedings.
- After the conference, the authors are encouraged to submit a full manuscript based on the proceedings to the Biomedicines Special Issue "Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021)" with a 20% discount on the Article Processing Charges.
Manuscripts for the proceedings issue must have the following organization:
First page:
- Title
- Full author names
- Affiliations (including full postal address) and authors’ e-mail addresses
- Abstract (200–250 words)
- Keywords
- Introduction
- Methods
- Results and Discussion
- Conclusions
- (Acknowledgements)
- References
Manuscripts should be prepared in MS Word or any other word processor and should be converted to PDF format before submission. The publication format will be PDF. The manuscript should be at least 3 pages (incl. figures, tables, and references) and should not exceed 6 pages.
Presentation Slides
Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the manuscript. Slides, if available, will be displayed directly in the website using the proprietary slides viewer at Sciforum.net. Slides can be prepared in exactly the same way as for any traditional conference where research results can be presented. Slides should be converted to PDF format before submission so that we can easily and automatically process them for online display.
Video Presentations
Besides their active participation within the forum, authors are also encouraged to submit video presentations. The video should be no longer than 20 minutes and be prepared in one of the following formats:
- MOV
- MPEG4
- MP4
- AVI
- WMV
- MPEGPS
- FLV
Authors that wish to present only a poster, i.e., without a proceedings paper, can do so in section I. Posters will be available on the conference website during and after the event. Similarly to papers presented at the conference, participants will be able to ask questions and make comments about the posters. Posters that are submitted without a paper will not be included in the proceedings of the conference.
Submission: Manuscripts should be submitted online at https://ecb2021.sciforum.net by registering and logging in to this website.
Accepted File Formats
- MS Word: Manuscript prepared in MS Word must be converted into a single file before submission. When preparing manuscripts in MS Word, the 1st International Electronic Conference on Microbiology Microsoft Word template file (see download below) must be used. Please do not insert any graphics (schemes, figures, etc.) into a movable frame which can superimpose the text and make layout very difficult.
1st International Electronic Conference on Biomedicine Microsoft Word template file
Manuscript Preparation
- Paper Format: A4 paper format, the printing area is 17.5 cm × 26.2 cm. The margins should be 1.75 cm on each side of the paper (top, bottom, left, and right sides).
- Paper Length: The conference proceedings paper should not be longer than 6 pages. The conference manuscript should be as concise as possible.
- Formatting/Style: The paper style of the journal Proceedings should be followed. You may download the template file to prepare your paper (see above). The full titles of the cited papers must be given. Reference numbers should be placed in square brackets [ ], and placed before punctuation; for example [4] or [1–3], and all the references should be listed separately and as the last section at the end of the manuscript.
- Authors List and Affiliation Format: Authors’ full first and last names must be given. Abbreviated middle name(s) can be added. For papers written by various contributors, a corresponding author must be designated. The PubMed/MEDLINE format is used for affiliations: complete street address information including city, zip code, state/province, country, and email address should be added. All authors who contributed significantly to the manuscript (including writing a section) should be listed on the first page of the manuscript, below the title of the article. Other parties who provided only minor contributions should only be listed under Acknowledgments. A minor contribution might be a discussion with the author, reading through the draft of the manuscript, or performing English corrections.
- Figures, Schemes, and Tables: Authors are encouraged to prepare figures and schemes in color. Full color graphics will be published free of charge. Figure and schemes must be numbered (Figure 1, Scheme I, Figure 2, Scheme II, etc.) and an explanatory title must be added. Tables should be inserted into the main text, and numbers and titles for all tables supplied. All table columns should have an explanatory heading. Please supply legends for all figures, schemes, and tables. The legends should be prepared as a separate paragraph of the main text and placed in the main text before a table, figure, or scheme.
Potential Conflicts of Interest
It is the authors’ responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state here “The authors declare no conflict of interest”. This should be conveyed in a separate “Conflict of Interest” statement preceding the “Acknowledgments” and “References” sections at the end of the manuscript. Financial support for the study must be fully disclosed under the “Acknowledgments” section.
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a Communication paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the Sciforum.net platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
Call for Papers
The 1st International Electronic Conference on Biomedicine will be held on 1–26 June 2021. ECB 2021 aims to promote and advance the exciting and rapidly changing field of Biomedicine. All proceedings will be held online at https://ecb2021.sciforum.net.
Topics of interest include, but are not limited to:
- Nanomedicine and Precision Medicine
- Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
- Cancer Therapeutics
- Metal-based Therapeutics in Preclinical and Clinical Developments
- Oncolytic Virus-mediated Immunotherapy
- Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
- Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
- Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
- Translational Biomarkers in Clinical Biomedicine and Precision Medicine
- G-protein-coupled Receptor Family
- Microbiota, Probiotics and Nutraceuticals: Preventive and Therapeutic Potential
ECB 2021 is an electronic conference sponsored by Biomedicines. Participation is free of charge for authors and attendees. Accepted papers will be gathered in the proceedings of the conference. Selected extended versions of the papers will be published in a Special Issue of Biomedicines and undergo full peer review (ISSN 2227-9059; impact factor: 4.717 (2020)) with a 20% discount on the article processing charge. ECB 2021 offers you the opportunity to participate in this international, scholarly conference without the concerns or expenditure of travel—all you need is your computer and access to the internet. We would like to invite you to attend this conference and present your latest work.
Abstracts (in English) should be submitted online by 16 March 2021 at https://ecb2021.sciforum.net. For accepted abstracts, the proceedings can be submitted by 30 April 2021. The conference will be held on 1–26 June 2021.
Paper Submission Guidelines
For information about the submission procedure and preparation of a full presentation, please refer to the "Instructions for Authors".
Time Schedule
- Abstract Submission: 16 March 2021
- Notification of Acceptance: 31 March 2021
- Paper Submission Deadline: 30 April 2021
- Conference Open: 1–26 June 2021
We thank you in advance for your attendance of this conference and look forward to a stimulating exchange.
Event Awards
To acknowledge the support of the conference esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to launch the Best Paper Award and Best Poster Award.
The Awards
The Best Paper Award is presented to the paper judged to make the most significant contribution to the conference.
The Best Poster Award was established to recognize the scientific merit exhibited in poster presentation and preparation.
Terms and Conditions:
Best Paper Award
As a sponsor, Biomedicines would like to award the best paper as elected by the conference committee. The award will consist of 500 Swiss Francs. We look forward to posting your contributions.
Criteria for Evaluation of Best Paper Award:
- Full paper must be submitted to ECB2021;
- Originality/novelty of the paper;
- Significance of content;
- Scientific soundness;
- Interest to the readers;
- English language and style.
Evaluation
- Each Evaluation Committee member will give an assessment for each applicant in terms of the criteria outlined above;
- The total score for each presentation will be ranked from highest to lowest;
- If two or more authors receive the same score, further evaluation will be carried out;
- All decisions made by the Evaluation Committee are final.
Best Poster Award
As a sponsor, Biomedicines would like to grant an award (500 Swiss Francs) for the best poster presented at the conference. This prize is awarded by a jury to the best designed poster presented at the conference.
Posters should have the following information.
- Title (with authors and affiliations)
- Introduction/Objectives/Aims
- Methods
- Results
- Conclusion
- References
- Acknowledgements
- Contact information
- A 3-minute video presentation
During the conference, the chair is invited to judge the quality of the 3-minute video presentation and poster. Criteria for judgement of the presentation will be the ability to summarize the content of the work and motivate the interest in looking at the poster. In addition, the clarity of poster and appearance quality will be considered.
S1. Nanomedicine and Precision Medicine
S2. Nutraceuticals, Nano Nutraceuticals and Nano Pharmaceuticals
S4. Metal-based Therapeutics in Preclinical and Clinical Developments
Session Chair
Dr. Muhammad Hanif, The University of Auckland, Auckland, New Zealand
S6. Neuroprotective Therapies in Spinal Cord Injury; the First and Necessary Step Towards the Cure
Show all published submissions (1) Hide published submissions (1)
Submissions
List of Papers (1) Toggle list
S7. Exploring Biomedicines in Behavioral Neurology and Neuropsychiatry
S8. Nanomaterials and Its Application in Biomedicine, including Drug/Gene/Vaccine Delivery, Imaging, Medical Devices and Surgical Implants
S9. Translational Biomarkers in Clinical Biomedicine and Precision Medicine
S10. G-protein-coupled Receptor Family
Show all published submissions (7) Hide published submissions (7)
Submissions
List of Papers (7) Toggle list